athira.com (ATHA) - התחייבויות לטווח ארוך להון

Athira Pharma, Inc. (ATHA) is developing unique brain regeneration methods for dementia, which is supported by the long-term debt-to-equity ratio. The current value of 0.02 captures the level of this metric. A stable staff of neurobiologists and expertise in FDA regulatory affairs guarantee product development. Meanwhile, patent protection for Alzheimer's molecules ensures sustainable margins and multi-year demand for the company.

Financial stability is critical for Athira Pharma, Inc. (ATHA), as it awaits catalysts in the development of drugs for cognitive disorders. The current long-term debt-to-equity ratio, equal to 0.02, reflects the company's reliance on external borrowings with maturities exceeding one year. This metric is calculated as the ratio of long-term liabilities to shareholders' equity. A reduction in this value minimizes bankruptcy risk. Investors should evaluate the balance between the absence of a debt load and the loss of tax advantages.